16 research outputs found

    Correlation between OSNA assay and histology results in the entire series of 903 SLNs. <i>Panel A:</i>

    Full text link
    <p>The histograms summarize the percentage of concordant and discordant results on SLNs analyzed by OSNA and histology. <b><i>Panel B:</i></b> Representative examples of CK19 immunostaining (immunoperoxidase) of a micrometastasis (a) and a macrometastasis (b) in two different SLNs compared to the matched OSNA curves (a-b) (scale bar = 90 µm). <b><i>Panel C:</i></b> The histograms show the distribution of −/negative, +/micrometastatic and ++/macrometastatic SLNs analyzed both by molecular and morphological methods. The percentage of micrometastases by OSNA was 11.9% and by histology 7.4%, whereas the percentage of macrometastases by OSNA was 10.4% and by histology 13.4%. Histology included H&E staining and IHC. OSNA−: <250; OSNA+ : >250≤5000; OSNA++: >5000 CK19 mRNA copies/µl.</p

    MCA of the 179 OSNA +/++ BC patients stratified by molecular subtypes and relationship between BC subtypes and ALND status in the subset of 91 OSNA+ BC patients.

    Full text link
    <p><b><i>Panel A:</i></b> The MCA graph demonstrates that ALND (+) is located in the quadrant containing the most aggressive phenotypes (T2 tumors, positive LVI, HER2 subtype, OSNA++) in contrast to ALND (−) which is associated to more favourable bio-pathological parameters (T1 tumors, absence of LVI, LA subtype). *LA: Luminal A; LB: Luminal B; HS: HER2 subtype; TN: Triple Negative <b><i>Panel B :</i></b> The histograms report the distribution of molecular subtypes in the 72 OSNA+ cases with ALND negative and CK19 mRNA <2000 copies/µl (range 270–1900). <b><i>Panel C</i></b><b> :</b> The histograms report the distribution of molecular subtypes in the 19 OSNA+ cases with ALND positive and CK19 mRNA >2000 copies/µl (range 2100–4600).</p

    Logistic regression analysis of negative factors predictive of ALND involvement.

    Full text link
    <p>ALND: axillary lymph node dissection; OR: odd ration; CI: confidence interval; LA: Luminal A; LB: Luminal B; HS: HER2 subtype; TN: Triple Negative; LVI: lymphovascular invasion; OSNA: one step nucleic acid amplification; OSNA+: >250≤5000 cytokeratinn 19 mRNA copies/µl; OSNA++: >5000 cytokeratin 19 mRNA copies/µl.</p

    Relationship between SLN status and bio-pathological parameters.

    Full text link
    <p>The histograms show that OSNA positive results are significantly correlated with <b><i>(Panel A)</i></b> poor differentiated tumor (p = 0.039), <b><i>(Panel B)</i></b> high proliferation index (p = 0.028) and <b><i>(Panel C)</i></b> presence of lymphovascular invasion (LVI p<0.0001).</p

    Cytokeratin 19 mRNA copy number distribution according to molecular subtypes.

    Full text link
    <p>Box Plot showing the distribution of cytokeratin 19 mRNA copy number in the five molecular subtypes. The Kruskall-Wallis test indicates a significant difference among groups (p<0.0001). Data are expressed on a log scale for presentation purposes.</p

    Relationship between number of SLNs tested by OSNA and ALND status.

    Full text link
    <p>The percentage of negative ALND was significantly higher in patients with 1 OSNA positive SLN (65.8% vs 34.2%). Conversely, the percentage of positive ALND was significantly higher in patients with 2 or more OSNA positive SLNs (66.7% vs 33.3%) (p = 0.004).</p
    corecore